Cliff Asness's XBI Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 7,388 shares of State Street SPDR S&P Biotech ETF (XBI) worth $740,343, representing 0.00% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 4 quarters.
Based on 13F filings, Cliff Asness has maintained this position in XBI for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2025, adding 2,167 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's State Street SPDR S&P Biotech ETF (XBI) Holding Value Over Time
Track share changes against reported price movement
Quarterly State Street SPDR S&P Biotech ETF (XBI) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2024 | +2,811 | New Buy | 2,811 | $90.06 |
| Q1 2025 | +2,167 | Add 77.09% | 4,978 | $81.10 |
| Q2 2025 | +1,834 | Add 36.84% | 6,812 | $82.93 |
| Q3 2025 | +576 | Add 8.46% | 7,388 | $100.21 |
Cliff Asness's State Street SPDR S&P Biotech ETF Investment FAQs
Cliff Asness first purchased State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, acquiring 2,811 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held State Street SPDR S&P Biotech ETF (XBI) for 4 quarters since Q4 2024.
Cliff Asness's largest addition to State Street SPDR S&P Biotech ETF (XBI) was in Q4 2024, adding 2,811 shares worth $253,154.
According to the latest 13F filing for Q3 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 7,388 shares of State Street SPDR S&P Biotech ETF (XBI), valued at approximately $740,343.
As of the Q3 2025 filing, State Street SPDR S&P Biotech ETF (XBI) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in State Street SPDR S&P Biotech ETF (XBI) was 7,388 shares, as reported at the end of Q3 2025.